Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Nitroxyl derivatives of rubomycin]

N M Emanuél', N P Konovalova, R F D'iachkovskaia

    Antibiotiki
    |November 1, 1982
    PubMed
    Summary

    New spin-labeled rubomycin analogs show reduced toxicity and enhanced antitumor effects. Ruboxyl-l demonstrates lower cardiotoxicity and no hemopoiesis inhibition, offering a promising alternative cancer treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The Effectiveness of Cyclic Hydroxamic Acid CHA-5 against Drug-Resistant P388 Leukemia Strains.

    Bulletin of experimental biology and medicine·2017
    Same author

    [Cyclic hydroxamic acids as chemosensitizers in cytostatic therapy].

    Voprosy onkologii·2013
    Same author

    [The use of hydroxamic acids and sodium nitrate to enhance the antitumor effect of cyclophosphamide].

    Voprosy onkologii·2013
    Same author

    [Antileukemic activity and development of resistance to cisplatin (CPT) and platinum (IV)-nitroxyl complex VS118].

    Voprosy onkologii·2011
    Same author

    Effect of nitric oxide donor, a modulator of tumor drug resistance, on cell death and p53 protein expression.

    Bulletin of experimental biology and medicine·2009
    Same author

    Effect of drug resistance modulator, NO donor, on membrane structure and function of membrane-bound Ca2+-activated Mg2+-dependent ATPase.

    Bulletin of experimental biology and medicine·2009

    Area of Science:

    • Pharmacology
    • Medicinal Chemistry
    • Oncology

    Background:

    • Rubomycin is an anthracycline antibiotic with significant antitumor activity.
    • However, its clinical use is limited by cardiotoxicity and myelosuppression.
    • Developing analogs with improved therapeutic profiles is crucial.

    Purpose of the Study:

    • To synthesize and evaluate novel rubomycin analogs.
    • To assess the toxic and antitumor effects of these new compounds.
    • To identify analogs with a better safety and efficacy profile than rubomycin.

    Main Methods:

    • Synthesis of spin-labeled and diamagnetic rubomycin analogs.
    • In vitro and in vivo studies to determine toxicity (cardiotoxicity, hemopoiesis inhibition).
    • Antitumor activity assays against relevant cancer models.

    Main Results:

    • Spin-labeled rubomycin derivatives exhibited the lowest toxicity and highest antitumor activity.
    • The diamagnetic analog showed antitumor effects comparable to rubomycin.
    • Ruboxyl-l displayed reduced cardiotoxicity compared to rubomycin.
    • Ruboxyl-l did not inhibit hemopoiesis at maximum tolerated doses.

    Conclusions:

    • Spin-labeled rubomycin analogs represent a promising class of anticancer agents.
    • Ruboxyl-l offers an improved safety profile regarding cardiotoxicity and hematological effects.
    • Further investigation of these analogs is warranted for potential clinical application.

    Related Experiment Videos